Rapid Reduction in Use: In a randomized double-blind clinical trial, both the 100mg and 300mg doses of SUBLOCADE® reduced opioid use frequency from over 43 instances per week at screening to fewer than three by week three, demonstrating significant efficacy in treating opioid use disorder.
Higher Dose Advantage: Participants using fentanyl daily or 14 or more times per week showed significantly higher abstinence rates with the 300mg dose compared to the 100mg, suggesting that high-frequency users may benefit from a higher maintenance dose, highlighting the importance of personalized treatment approaches.
Good Safety Profile: The trial results indicated that injection-site reactions were more common in the 300mg group but were mild to moderate and did not lead to discontinuation, reinforcing confidence in the drug's safety for clinical use.
Addressing the Opioid Crisis: The findings provide evidence for clinicians navigating the complexities of opioid use disorder in the fentanyl era, emphasizing the need for treatment approaches that adapt to the realities of today's opioid crisis to enhance patient recovery chances.
INDV
$35.83+Infinity%1D
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.380
Low
35.00
Averages
38.67
High
41.00
Current: 35.380
Low
35.00
Averages
38.67
High
41.00
Morgan Stanley
Overweight
maintain
$28 -> $36
2025-12-03
Reason
Morgan Stanley
Price Target
$28 -> $36
2025-12-03
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Indivior to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Northland
Outperform
upgrade
$30 -> $40
2025-10-31
Reason
Northland
Price Target
$30 -> $40
2025-10-31
upgrade
Outperform
Reason
Northland raised the firm's price target on Indivior to $40 from $30 and keeps an Outperform rating on the shares. The firm's upward revision reflects confidence in Sublocade's prospects, combined with Indivior's cost containment initiatives, the analyst tells investors.
Craig-Hallum
Buy
maintain
$34 -> $41
2025-10-31
Reason
Craig-Hallum
Price Target
$34 -> $41
2025-10-31
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Indivior to $41 from $34 and keeps a Buy rating on the shares. The firm cites the company's Q3 massive beat, delivering revenue of $314M, beating Street estimates of $261.9M, with broad-based strength from both Sublocade and Suboxone.
Piper Sandler
NULL -> Overweight
upgrade
$27 -> $41
2025-10-31
Reason
Piper Sandler
Price Target
$27 -> $41
2025-10-31
upgrade
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on Indivior to $41 from $27 and keeps an Overweight rating on the shares. The firm notes Indivior reported Q3 2025 diluted non-GAAP earnings per share of 72c on revenue of $314M, compared to Street estimates of 41c and $262M, respectively. Management is now guiding to Sublocade worldwide sales of $825M-$845M, up from the previous range of $765M-$785M, and now implying annual growth of about 10% at the midpoint.
About INDV
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
